

Docket No. 2519-US-NP

RECEIVED
CENTRAL FAX CENTER

FEB 08 2007

3. Remarks

This Amendment and Reply is filed in response to the Office Action having a mailing date of August 8, 2006. Claims 15-30, 32, 35, and 37-40 are currently pending. All claims stand rejected as being *prima facie* obvious over the cited art.

Applicants have amended Claims 15, 29, 30, 32, and 40 to specify that the affinity constant for TACI (SEQ ID NO:2) and TACI-L (SEQ ID NO:4) used in the screening methods is from 1.53×10^{-9} to 2.2×10^{-9} . Support for the amendments may be found at page 15, lines 5-12. Applicants submit that no new matter has been added.

Gross, Bram, and Yu do not teach or suggest that the affinity constant for TACI and TACI-L is from 1.53×10^{-9} to 2.2×10^{-9} . Applicants note that *Gross* teaches at paragraph [0110], Table 5 that the affinity constant for a soluble form of Neutrokin α (aka *ztnf4*, TACI-L) and TACI-expressing BHK cells is 1.11×10^{-9} , which is outside the range in Applicants' claimed invention.

As such, Applicants respectfully request that the rejection under 35 U.S.C. §103(a) be removed.

Respectfully submitted,


James E. Klaniecki
Registration No. 38,207

Immunex Corporation
Law Department
1201 Amgen Court West
Seattle, Washington 98119-3105
Phone: 206-265-7000

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the date indicated below.

Signed: 
Nanci M. KertsonDate: Feb. 8, 2007